Back to journals
Academic Journal

Journal of Affective Disorders

55 Papers Indexed in Blossom

Published Papers

Open Accessindividual

Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study

This retrospective naturalistic study (n=178) examined whether benzodiazepines, lithium or lamotrigine altered the antidepressant effects of subcutaneous esketamine in people with treatment-resistant depression. Depression scores fell over six weeks, but benzodiazepine use was linked to higher symptom levels during treatment, while lithium and lamotrigine were not.

Published
Journal
Journal of Affective Disorders
Authors
Atidio, J. P., Delfino, R. S., Garios, I. S., de Brito, C. S. G. F., Gerheim, Y. P., de Almeida e Vasconcelos, G. M., Piloto, R., Ferro, M. D., de Souza Júnior, R. O. P., Surjan, J. C., Lacerda, A. L.
Paywallindividual

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis

This secondary analysis (n=79 of n=233) of a Phase II randomised trial examined whether therapeutic alliance or the psychedelic experience itself better predicted antidepressant outcomes in people with treatment-resistant depression (TRD) receiving psilocybin (25 mg), finding that measures of the psychedelic experience were more strongly associated with reduced depression scores than pre-dosing therapeutic alliance, though alliance did appear to modestly facilitate the quality of the psychedelic experience.

Published
Journal
Journal of Affective Disorders
Authors
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Carhart-Harris, R., Croal, M., Feifel, D., Hellerstein, D. J., Husain, M. I., Kelly, J. R., Kirlic, N., Licht, R. W., Marwood, L., Nowakowska, A., Páleníček, T., Repantis, D., Schoevers, R. A., Simmons, H., Soares, J. C., Somers, M., Tsai, J., Wahba, M., Williams, E., Young, A. H., Young, M. B., Zisook, S., Malievskaia, E.
Paywallindividual

Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans

This secondary analysis of an open-label study (n=30) of male Veterans with traumatic brain injury found that greater intensity of mystical experiences during magnesium-ibogaine treatment was associated with larger reductions in PTSD severity both immediately and one month post-treatment, as well as greater reductions in peak alpha frequency at one month.

Published
Journal
Journal of Affective Disorders
Authors
Brown, R. E., Lissemore, J. I., Shinozuka, K. F., Coetzee, J. P., Faerman, A., Olash, C. A., Geoly, A. D., Buchanan, D. M., Cherian, K. N., Chaiken, A., Shamma, A., Sridhar, M., Hunegnaw, S. A., Johnson, N. D., Rolle, C. E., Adamson, M. M., Williams, N. R.
Open Accessindividual

Naturalistic psychedelic use and changes in depressive symptoms

This longitudinal observational study (n=12,345) of U.S. residents found that naturalistic psychedelic use (n=505, 4.1% of participants) was associated with modest increases in depressive symptoms, particularly when occurring in 'risk contexts' characterised by negative mindset and lack of psychological support, with challenging psychedelic experiences mediating this relationship and suggesting that unsupervised psychedelic use may not be generally therapeutic and could worsen depression under certain circumstances.

Published
Journal
Journal of Affective Disorders
Authors
Simonsson, O., Hendricks, P. S., Swords, C. M., Osika, W., Goldberg, S. B.
Paywallindividual

Long-term outcomes of single-dose psilocybin for U.S. military Veterans with severe treatment-resistant depression - 12-month data from an open-label pilot study

This open-label follow-up study (n=10) of Veterans with severe treatment-resistant depression (TRD) found that a single dose of psilocybin (25mg) significantly reduced depression for up to 12 months, though effects began to wane after 6 months, with 40% maintaining response and 30% maintaining remission at the 12-month follow-up.

Published
Journal
Journal of Affective Disorders
Authors
Ellis, S., Bostian, C., Donnelly, A., Feng, W., Eisen, K., Lean, M., Conlan, E., Ostacher, M., Aaronson, S., Suppes, T.
Paywallindividual

Economic evaluation of subcutaneous ketamine injections for treatment resistant depression: A randomised, double-blind, active-controlled trial - The KADS study

This cost-utility analysis, alongside a randomised controlled trial (n=174), compared subcutaneous ketamine (twice-weekly for 4 weeks) with midazolam in treatment-resistant depression. Including midazolam costs, ketamine raised QALYs (0.435 vs 0.352) and was dominant with an 89-91 % chance of costing < $50 000/QALY, but once these comparator costs were excluded ketamine was no longer cost-effective (ICER ≈ $108 500-$251 250/QALY, ≤ 5 % probability).

Published
Journal
Journal of Affective Disorders
Authors
Chatterton, M. L., Perez, J. K., Thai, T., Faller, J., Loo, C. K., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., Glue, P., Sarma, S., Hadzi-Pavlovic, D., Dong, V., Martin, D., Mitchell, P. B., Berk, M., Carter, G., Hackett, M., Hood, S., Somogyi, A. A., Rodgers, A., Mihalopoulos, C.

Quick Facts

Papers Indexed
55
h-Index
245
Open Access
No
Publisher
Elsevier
Country
Netherlands
Website
Visit